Study offers surprising insights into vegetarians' psyches
A study of more than 3,500 adults in Poland and the US found that vegetarians are more likely to value social status and personal ambition than meat -eaters.
Vegetarians showed a greater appetite for novelty and challenge, aligning with values that improve their social standing.
Meat-eaters were found to prioritise tradition, conformity, benevolence, and security.
Professor John Nezlek noted the common association between meat and masculinity, saying that vegetarians are often perceived as more benevolent, but the study found the opposite.
The study suggests vegetarians are independent thinkers who strongly hold their beliefs, willing to stand by their principles as a social minority.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
an hour ago
- Daily Mail
Legendary astronaut reveals the best view of the moon from Earth happens in just HOURS... here's how to see it
Legendary NASA astronaut has expressed excitement for the appearance of a Strawberry Moon tonight, saying it will be the 'best lunar views in 20 years' Buzz Aldrin, the second man to walk on the moon, shared on social media that the moon 'is projected to have a rather low arc across the sky due to the lunar standstill and will appear quite large.' The low arc is caused by a phenomenon called a 'major lunar standstill,' which occurs once every 18.6 years. During this time, the moon's orbit reaches its steepest tilt, causing it to rise and set at its most extreme points on the horizon. As a result, summer full moons like tonight's travel much lower in the sky than usual. The full moon will rise just after sunset on Tuesday, June 10, and shine brightest early Wednesday morning, June 11. The full phase will peak at 3:44am ET, but the best viewing time is shortly after moonrise Tuesday evening. Skywatchers in the Northern Hemisphere will see the moon glowing orange or yellow near the southern horizon, thanks to atmospheric light scattering. The name 'Strawberry Moon' is a traditional title given to the full moon that appears in June and has historically coincided with the start of the strawberry harvest. Contrary to popular belief, it does not refer to the moon's color or any resemblance to the fruit itself. Full moons have long been assigned nicknames based on the month they occur, a practice dating back hundreds of years. NASA notes this year's Strawberry Moon will also appear near the bright center of the Milky Way, visible during the June through August 'core season.' The moon's unusually low path tonight is a direct result of its 18.6-year lunar cycle, known as a lunistice, a point when the moon's orbit tilts to its greatest angle relative to Earth's equator. This tilt means the moon rises and sets farther north or south on the horizon than usual, following a shallower or higher arc depending on the season. NASA explains this occurs because the moon's tilted orbit interacts with Earth's own tilted axis and orbit around the sun, causing long-term shifts in the moon's apparent trajectory. At this time, the 'moon illusion' makes the moon appear larger near the horizon, a psychological effect that doesn't change the moon's actual size but makes the sight especially striking. The moon's glow often appears soft orange or yellow near the horizon because Earth's atmosphere scatters shorter blue wavelengths, allowing longer red and yellow light to reach the eye, similar to a sunset effect. For those hoping to catch the Strawberry Moon, open fields, hilltops or coastal areas facing the southeast horizon offer the clearest views. No special equipment is needed to enjoy the event, though binoculars or a telescope can reveal more detail. The moon's shifting rise and set points have been observed and tracked by cultures worldwide for centuries.
The Independent
an hour ago
- The Independent
People with Covid-like symptoms took almost a year before feeling like themselves again, researchers say
Did you have Covid-like symptoms? It may take nine months or even longer to start feeling like yourself again. Researchers at UCLA found that 20 percent of patients with those symptoms continued experiencing suboptimal quality of life for nearly a year after infection. Whereas, physical well-being returned after only three months. "We have newly recognized the difference in recovery with respect to mental vs. physical well-being after a COVID infection," Lauren Wisk, an assistant professor of medicine at UCLA, said in a statement. "The findings showed that health care professionals need to pay more attention to their patients' mental well-being after a Covid infection and provide more resources that will help improve their mental health, in addition to their physical health,' she added. Wisk was one of the lead authors of the Centers for Disease Control and Prevention-funded study that was published Tuesday in the journal Open Forum Infectious Diseases. The study compared people who sought treatment for Covid-like symptoms. Of those, 75 percent tested positive for the virus. The rest were negative. Of the 4,700 participants who experienced the symptoms between mid-December 2020 and late August 2022, the people who were positive for Covid were statistically likelier to return to optimal health-related quality-of-life than their Covid-negative counterparts in the year following the infection. The authors said the findings suggest that health authorities may have previously underestimated the long-term effects of non-Covid infections on a patient's well-being. To reach these conclusions, researchers analyzed responses from nearly 1,100 Covid-positive patients and 317 Covid-negative negative patients, assessing aspects including physical function, anxiety, depression, fatigue, social participation, sleep disturbance, pain interference and cognitive function. They found that approximately one in five of those who were part of the study remained in poor overall quality of life, with a high likelihood of self-reporting long Covid for up to a year after initial infection. 'In this large, geographically diverse study of individuals with 12 months of follow-up after Covid-19-like illness, a substantial proportion of participants continued to report poor [overall quality of life], whether or not the inciting acute symptoms were due to SARS-CoV-2 or another illness,' they said. Mental well-being recovered gradually, with significant improvements manifesting between six and nine months after infection, researchers found. The authors said further research was needed, noting that it remains unclear which conditions the symptomatic Covid-negative patients were suffering from and that Covid tests can yield both false-positive and false-negative results. The common cold, allergies, flu and Covid share many similar symptoms. "Future research should focus on how to improve the treatment models of care for patients who continue to experience Covid-19 symptoms and their impact on patients' quality of life, especially as one in five patients may continue to suffer over a year after their initial infection, which likely reflects long Covid," Wisk said.
The Independent
4 hours ago
- The Independent
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. A request for comment from the drugmakers Novo Nordisk and Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
